SP4

Across TCGA pan-cancer cohorts, SP4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SP4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SP4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SP4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.754	0.429	.018	16	view →
LUAD	OS	Median	All	1.000	0.791	.013	14	view →
PDAC	DFS	Tertile	All	0.891	0.727	.018	11	view →
UCEC	OS	Tertile	All	0.887	1.000	.015	8	view →
LSCC	DFS	Quartile	All	1.000	0.966	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SP4–CCRCC (OS)

Open the CCRCC breakdown →